Nanjing Well Pharmaceutical Co Ltd Asset Resilience Ratio
Nanjing Well Pharmaceutical Co Ltd asset resilience ratio. Nanjing Well Pharmaceutical Co Ltd (603351) has an Asset Resilience Ratio of 0.19% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Nanjing Well Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Nanjing Well Pharmaceutical Co Ltd (2019–2023)
Asset resilience ratio of Nanjing Well Pharmaceutical Co Ltd from 2019 to 2023. This chart shows how Nanjing Well Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read Nanjing Well Pharmaceutical Co Ltd (603351) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Nanjing Well Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 603351 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥5.00 Million | 0.19% |
| Total Liquid Assets | CN¥5.00 Million | 0.19% |
Asset Resilience Insights
- Limited Liquidity: Nanjing Well Pharmaceutical Co Ltd maintains only 0.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Nanjing Well Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Nanjing Well Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Nanjing Well Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2019–2023)
Nanjing Well Pharmaceutical Co Ltd asset resilience ratio by year from 2019 to 2023. The table below shows the annual Asset Resilience Ratio data for Nanjing Well Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.05% | CN¥1.25 Million ≈ $183.19K |
CN¥2.28 Billion ≈ $333.48 Million |
+0.00pp |
| 2022-12-31 | 0.05% | CN¥1.11 Million ≈ $161.86K |
CN¥2.14 Billion ≈ $312.88 Million |
-1.37pp |
| 2021-12-31 | 1.42% | CN¥26.24 Million ≈ $3.84 Million |
CN¥1.84 Billion ≈ $269.46 Million |
-10.60pp |
| 2020-12-31 | 12.02% | CN¥196.71 Million ≈ $28.78 Million |
CN¥1.64 Billion ≈ $239.46 Million |
+5.83pp |
| 2019-12-31 | 6.19% | CN¥90.31 Million ≈ $13.22 Million |
CN¥1.46 Billion ≈ $213.39 Million |
-- |
About Nanjing Well Pharmaceutical Co Ltd
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China and internationally. The company offers excipients for injection, oral, and topical applications; and active pharmaceutical ingredients (API), such as polidocanol and polyethylene glycol 3… Read more